

#### WORLD INTELLECTUAL PROPERTY ORGANIZATION

#### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5:		(11) International Publication Number:	WO 93/11757
A61K 31/135, 47/48, 9/127 A61K 9/107	A1	(43) International Publication Date:	24 June 1993 (24.06.93)

(21) International Application Number:

PCT/FI92/00339

(22) International Filing Date:

10 December 1992 (10.12.92)

(30) Priority data: 9126209.7

10 December 1991 (10.12.91) GB

(71) Applicant (for all designated States except US): ORION-YH-TYMÄ OY [FI/FI]; Orionintie 1, SF-02200 Espoo (FI).

(72) Inventors; and
(75) Inventors/Applicants (for US only): JALONEN, Harry, Gösta [FI/FI]; Hurtinkatu 4a, SF-20600 Turku (FI). HEIKKILÄ, Terttu, Marita [FI/FI]; Vuorikatu 7aB33, SF-20700 Turku (FI). JALONEN, Hannu, Uolevi [FI/FI]; Rakuunatie 60A6, SF-20720 Turku (FI). KANGAS, Lauri, Veikko, Matti [FI/FI]; Pasantie 3B, SF-21280 Raisio (FI). LAMMINTAUSTA, Risto, Arvo, Sakari [FI/FI]; Meltoistentie, SF-20900 Turku (FI). KURKELA, Kauko, Oiva, Antero [FI/FI]; Pampinkuja IC, SF-20900 Turku (FI). Turku (FI).

(74) Agent: ORION CORPORATION; c/o Orion-Farmos Pharmaceuticals, Patent Department, P.O. Box 65, SF-02101 Espoo (FI).

(81) Designated States: AU, BG, CA, CS, FI, HU, JP, KR, NO, NZ, PL, PT, RO, RU, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published

With international search report.

(54) Title: DRUG FORMULATIONS FOR PARENTERAL USE

#### (57) Abstract

This invention relates to parenteral preparations of antiestrogens such as toremifene, desmethyl toremifene, tamoxifen or desmethyltamoxifen. The preparations can be emulsions, liposomes or aqueous solutions of cyclodextrin-drug complexes. Particularly the invention relates to a parenteral drug formulation comprising a complex having a 2-hydroxypropyl cyclodextrin component and including an active drug substance selected from the group consisting of toremifene, desmethyl toremifene, tamoxifen and desmethyltamoxifen or a pharmaceutically acceptable non-toxic salt thereof, said complex being present either in an aqueous solution or emulsion or loaded into a liposome.

EST AVAILABLE COPY

ATMORNEY DOCKET NUMBER: (0177-191-999 SERIAL NUMBER: 10/603,115

REFERENCE: B115



## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



#### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5:		11) International Publication Number: WO 93/1175
A61K 31/135, 47/48, 9/127 A61K 9/107	A1	43) International Publication Date: 24 June 1993 (24.06.93)
(21) International Application Number: PCT/FI (22) International Filing Date: 10 December 1992		Pharmaceuticals, Patent Department, P.O. Box 65, SI
(30) Priority data: 9126209.7 10 December 1991 (10.12	2.91) (	(81) Designated States: AU, BG, CA, CS, FI, HU, JP, KR, NG NZ, PL, PT, RO, RU, UA, US, European patent (AT BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC NL, PT, SE).
<ul> <li>(71) Applicant (for all designated States except US): OR. TYMÄ OY [FI/FI]; Orionintie 1, SF-02200 Es</li> <li>(72) Inventors; and</li> <li>(75) Inventors/Applicants (for US only): JALONEN Gösta [FI/FI]; Hurtinkatu 4a, SF-20600 Tu HEIKKILÄ, Terttu, Marita [FI/FI]; Vuorikat SF-20700 Turku (FI). JALONEN, Hannu, Uc FI]; Rakuunatie 60A6, SF-20720 Turku (FI). K</li> </ul>	ipoo (F N, Hai irku (F tu 7aB olevi [I	Published  With international search report.
Lauri, Veikko, Matti [FI/FI]; Pasantie 3B, SF-2 sio (FI). LAMMINTAUSTA, Risto, Arvo, Sa FI]; Meltoistentie, SF-20900 Turku (FI). KU Kauko, Oiva, Antero [FI/FI]; Pampinkuja 1C, Turku (FI).	11280 R Ikari [I JRKEI	

(54) Title: DRUG FORMULATIONS FOR PARENTERAL USE

#### (57) Abstract

This invention relates to parenteral preparations of antiestrogens such as toremifene, desmethyl toremifene, tamoxifen or desmethyltamoxifen. The preparations can be emulsions, liposomes or aqueous solutions of cyclodextrin-drug complexes. Particularly the invention relates to a parenteral drug formulation comprising a complex having a 2-hydroxypropyl cyclodextrin component and including an active drug substance selected from the group consisting of toremifene, desmethyl toremifene, tamoxifen and desmethyltamoxifen or a pharmaceutically acceptable non-toxic salt thereof, said complex being present either in an aqueous solution or emulsion or loaded into a liposome.

#### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
ÄÜ	Australia	GA	Gabon ·	MW	Malawi
BB	Barbados	CB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinca	NO	Norway
BF	Burking Faso	GR	Greece	NZ	New Zealand
BC	Bulgaria	HU	Hungary	PL	Poland
BJ	Bunin	IE	Ireland	PT	Portugal
BR	Bazil	ıπ	Italy	RO	Romania
ČĀ.	Canada	JP.	Junan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic	SD.	Sudan
	•	•••	of Korea	SE	Sweden
CG	Congo Switzerland	KR	Republic of Korea	SK	Slovak Republic
CH	=	V7	Kazakhstun	SN	Senegal
CI	Our d'Ivoire	LI	Liuchtenstein	รับ	Soviet Union
CM	Cameroon	· ŁK	Sri Lanka	TD	Chad
cs	Czechuslovakia -	L.U	Luxembourg	TG	Togo
CZ	Czech Republic	. MC	Monaco	UA	Ukrainu
DE	Germany	MG		us	United States of America
DK	Denmark		Midagascar	YN	Vict Nam
ES	Spain	Ml.	Mali	••••	7.00
FI	Finland	· MN	Mongolia		

WO 93/11757

1

Drug formulations for parenteral use

This invention relates to drug formulations of antiestrogens, particularly antiestrogens comprising a triphenylbutene moiety, for use in parenteral administration.

Toremifene, desmethyl toremifene, desmethyl tamoxifen and tamoxifen are all examples of substituted triphenylbutenes useful in cancer therapy. Reference is made to US 4696949, US 4990538 and US 4356516. They can all be described with the formula

in which  $R_1$  is  $CH_3$  or H and  $R_2$  is H or Cl.

The compounds mentioned above have the following values of  $R_1$  and  $R_2$ ;

	R <sub>1</sub>	R <sub>2</sub>
toremifene	CH <sub>3</sub>	Cl
desmethyl toremifene	H	Cl
tamoxifen	сн3	H
desmethyl tamoxifen	H	Н

A common feature of these antiestrogens is their poor solubility in water. Thus, parenteral administration of these drugs cannot be accomplished simply by an aqueous solution of the active ingredients.

There is a clear need for parenteral formulations of the anticancer antiestrogens. Injectable high-concentration toremifene formulations will have important clinical benefit

in the attempts to reach high concentrations in tissue. This is necessary especially when combinations of toremifene with cytotoxic drugs are given to a patient. As shown by DeGregorio et al (J Clinical Oncology, vol 7, No 9,1989: 1359 - 1364.) high plasma concentrations are more effective in reversing multidrug resistance than low concentrations. An injectable formulation enables high peak concentrations in blood and tissues without exposing the patient to long-term treatment;

- 2) when given locally into a tumor. This enables a high and efficacious concentration in the tumor to be achieved;
- when used topically in a benign estrogen-dependent lesion like cystic mastalgia, where toremifene can be injected directly into a painful cyst;
- 4) when spreading toremifene topically onto palpable and subcutaneous breast cancer metastases;
- 5) when an intravesical installation is given for the therapy of superficial bladder cancer. In this indication to to may well be used together with other anticancer drugs to enhance their efficacy;
- 6) when an intraperitoneal solution is given for the treatment of certain types of overian cancer;
- 7) when other topical, estrogen-dependent lesions are treated with an antiestrogen.

The parenteral drug formulations according to this invention include emulsions, aqueous solutions of cyclodextrin - drug complexes and liposomes.

Dissolution properties of drugs can be significantly improved by complexation of the drug substance with cyclodextrins. Cyclodextrins (including  $\alpha$ ,  $\beta$  and  $\Gamma$  cyclodextrins and their derivatives) are all cyclic oligomers of glucose. The

cyclodextrins can form inclusion complexes with drugs in that the drug molecule is included in the lipophile-seeking cavities of the cyclodextrin molecule. Therefore the cyclodextrins effectively solubilize lipophilic drugs into aqueous media. The use of cyclodextrins in the pharmaceutical field has been described e.g. in Drug Development and Industrial Pharmacy, 17(11), 1503-1549, 1991.

With respect to the antiestrogens mentioned above, however, no parenteral drug formulations based on complexation of the active drug substance with 2-hydroxypropyl cyclodextrins are known in the art. One object of this invention is a parenteral formulation based on a 2-hydroxypropyl cyclodextrin, preferably 2-hydroxypropyl β-cyclodextrin or 2-hydroxypropyl-r-cyclodextrin, complex including an active drug substance selected from the group consisting of toremifene, desmethyltoremifene, tamoxifen and desmethyltamoxifen or a pharmaceutically acceptable non-toxic salt thereof, said complex being present in an aqueous solution.

Emulsions of the antiestrogens mentioned above can be made by dispersing the drug or a cylodextrin complex of said drug into a pharmaceutically acceptable emulsifier, and optionally adding a stabilizing agent.

Parenteral administration of the drugs mentioned above may also be accomplished by aqueous solutions of liposomes containing said drug or a salt thereof. Liposomes are spherical particles in an aqueous medium, formed by a lipid bilayer enclosing an aqueous compartment. The lipid surface may be either unilamellar or multilamellar. The liposomes may be loaded with either hydrophobic or hydrophilic drug substances.

Another object of the invention is a parenteral formulation based on the drug substance as such loaded into liposomes. Such liposomes can be made by dissolving the drug or drug-cyclodextrin.complex together with a phospholipid component, preferably DMPG (dimyristoylphosphatidylglycerol) and/or POPC

PCT/FI92/00339

WO 93/11757

(= 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphorylcholine), in a chloroform - methanol mixture, evaporating the solvent, dissolving the residue into water followed by homogenization. According to this invention liposomes can be made directly by dissolving the drug or the drug-cyclodextrin complex and phospholipid component directly in water without foregoing dissolving into chloroform - methanol mixture.

Another object of this invention is a parenteral formulation based on a 2-hydroxypropyl cyclodextrin, preferably 2-hydroxypropyl  $\beta$ -cyclodextrin or 2-hydroxypropyl  $\Gamma$ -cyclodextrin, complex including an active drug substance selected from the group consisting of toremifene, desmethyl toremifene, tamoxifen and desmethyltamoxifen or a pharmaceutically acceptable nontoxic salt thereof, said complex being loaded into a liposome.

# Preparation of the antiestrogen-2-hydroxypropyl cyclodextrin complexes:

A weighed amount of 2-hydroxypropyl cyclodextrin was dissolved into distilled water by shaking with a shaker. The so formed clear solution was equilibrated with a large excess of antiestrogen at the boiling point. After removing the almost clear solution the excess of antiestrogen started to precipitate. The solution was kept overnight at room temperature and the excess of precipitated antiestrogen was removed by centrifugation.

Measurement by HPLC of the solubility of the anti-estrogen in an aqueous solution of 2-hydroxypropyl cyclodextrin.

The fully automated HPLC apparatus (Hewlett-Packard, USA) consisted of a pump 1090, an autosampler and autoinjector (79847A) with an injection volume of 10 ul and a fixed wavelength UV detector, 280 nm (79881A). The chromatograms and peak areas were recorded with an integrator 3393. The separations were carried out at room temperature on a 35 \*

4.6 mm stainless steel column (packed with 3-µm spherical octadecylsilanebonded silica particles; HS-3 C-18, (Perkin-Elmer, USA)

The mobile phase consisted of a mixture of acetonitrile: 0.05 M aqueous phosphate buffer containing 0.004 M of dimethyloctyl amine with a pH of 7.4. The flow rate was 0.8 ml/min.

#### Preparation of the liposomes:

- 1) Liposomes based on cyclodextrin drug complexes and prepared by dissolving the components in an organic solution
- 2-hydroxypropyl- $\beta$ -cyclodextrin (12 mg), POPC (32 mg), cholesterol (4 mg), DMPG (dimyristoylphosphatidylglycerol) (8 mg) and toremifene citrate (2 mg) were dissolved in choloroform methanol (2:1) and evaporated. The residue was dissolved in water and homogenized by sonication (Labsonic U, 50 W). The stability of the solution was good; no turbidity was observed after one month in room temperature.
- 2) Liposomes based on cyclodextrin drug complexes and prepared by dissolving and homogenizing components directly in water
- 2-hydroxypropyl-β-cyclodextrin (24 mg), DMPG (dimyristo-ylphosphatidylglycerol) (16 mg) and toremifene citrate (2 mg) were simultaneously dissolved in 2 ml water and homogenized by sonication (Labsonic U, 50 W). The final solution was as clear as the solution above. The mean particle diameter of these two solutions were about 100 nm (Nicomp 370/HPL high power laser option). The solution was stable after one week storage at room temperature.
- 3) Liposomes which were not based on cyclodextrin complexes

6

Preparation of these solutions was attempted by dissolving the components directly into water. The only composition which gave a clear or slightly opalescent solution was DMPG (16 or 32 mg), toremifene citrate (2 mg) dissolved and homogenized by sonication (50 W) in 2 ml water. The stability of the solutions were not however good enough; solutions became a bit turbid in one month storage at room temperature, e.g., the composition toremifene citrate (2 mg), DMPG (32 mg) and cholesterol (4 mg) was not able to dissolve and homogenized in 2 ml water.

These results indicate that stable liposomes cannot be achieved in the absence of a cyclodextrin component especially if the drug and phosphiolipid are mixed directly into water.

However, cyclodextrin-free liposomes can be made by mixing the ingredients first in chloroform/ethanol (2:1) as described above for the cyclodextrin-containing liposomes.

#### Solubility results

**Formulation** 

Toremifene solubility

mq of toremifene
ml of cyclodextrin-water soln.

500 mg β-HPC/ml of aqueous soln. 250 " 125 " 63 " 25 " 0 "	87.7 53.0 21.7 14.1 7.4 0.3
$\beta$ -HPC = 2-hydroxypropyl- $\beta$ -cyclodextrin	ı
500 mg r-HPC/ml of aqueous soln. 250 125	125.4 61.1 36.3

Γ-HPC = 2-hydroxypropyl-Γ-cyclodextrin

#### Tamoxifen solubility

# mg of tamoxifen ml of cyclodextrin-water soln.

500 250	mg	β-HPC/ml	of	aqueous	soln.	•	67.4 43.3
125		. **		•			23.5
63					4.		13.3
25		••				•	6.1
U		#					< 1.0

Desmethyl toremifene solubility

mq of desmethyl toremifene ml of cyclodextrin-water soln.

125 mg  $\beta$ -HPC/ml of aqueous soln.

21.0

The pharmacokinetics of the toremifene formulations described above, when give intravenously, resemble closely those of perorally given toremifene. However, during the first minutes and 1-2 hours the concentrations of the intravenously given drug are high, while the drug, when given per os, has not yet been absorbed completely from the gastrointestinal tract.

#### Preparation of emulsions:

Emulsions prepared by dissolving the drug in a commercial fat emulsion.

The commercial fat emulsion used was Emulsan® 20 % (manufacturer Leiras-Kabi Infusion Ltd., Finland). Different amounts of toremifene citrate were dissolved in Emulsan solution and homogenized by sonication (Labsonic U, 50 W). The toremifene concentrations were 10 mg/ml, 14 mg/ml and 20 mg/ml. After the homogenization the samples were filtered through the 0.2  $\mu$ m, 0.45  $\mu$ m and 1.2  $\mu$ m filters.

The concentration of toremifene was determined from the filtrate with a spectrofotometric method using the wave length of 278 nm. The samples were dissolved in methanol and diluted in the concentration of 0.02 mg/ml.

The results are presented in the following table:

Concentration before filtration [mg/ml]	Size of the filter [µm]	Concentration after filtration [mg/ml]
10	0.2 0.45 1.2	4.4 4.0 4.4
14	0.45 1.2	4.3 3.7
20	0.45 1.2	3.6 3.6

The results show that the solubility of toremifene can be increased considerably by encapsulating the toremifene in an emulsion droplet.

PCT/F192/00339

WO 93/11757

9

#### Claims

- A parenteral drug preparation in the form of an emulsion or liposome of an active drug substance selected from the group consisting of toremifene, desmethyl toremifene, tamoxifen and desmethyltamoxifen or a pharmaceutically acceptable non-toxic salt thereof.
- A preparation according to claim 1 where the drug is toremifene or its non-toxic, pharmaceutically acceptable salt.
- A parenteral drug formulation comprising an aqueous solution of a complex which comprises a 2-hydroxypropyl cyclodextrin component and an active drug component in which the active drug is selected from the group consisting of toremifene, desmethyl toremifene, tamoxifen and desmethyl tamoxifen or a pharmaceutically acceptable non-toxic salt thereof.
- 4. A formulation according to claim 3 where the 2hydroxypropyl cyclodextrin component is 2hydroxypropyl-β-cyclodextrin.
- A formulation according to claim 3 where the 2hydroxypropyl cyclodextrin component is 2hydroxypropyl-r-cyclodextrin.
- A formulation according to claim 3 to 5 where the drug is toremifene or its non-toxic pharmaceutically acceptable salt.
- 7. A parental drug formulation comprising an emulsion or liposome comprising a complex which comprises a 2-hydroxypropyl cyclodextrin component and an active

drug component in which the active drug is selected from the group consisting of toremifene, desmethyl toremifene, tamoxifen and desmethyltamoxifen or a pharmaceutically acceptable non-toxic salt thereof.

- 8. A formulation according to claim 7 where the 2hydroxypropyl cyclodextrin component is 2hydroxypropyl-β-cyclodextrin.
- 9. A formulation according to claim 7 or 8 where the drug is toremifene or its non-toxic pharmaceutically acceptable salt.
- 10. A method of treatment of an estrogen-dependent tumor in a mammal comprising administering parenterally to said mammal an amount of a formulation as claimed in claim 1 sufficient to produce the desired effect.
- 11. A method of treatment of an estrogen-dependent tumor in a mammal comprising administering parenterally to said mammal an amount of a formulation as claimed in claim 3 sufficient to produce the desired effect.
- 12. A method of treatment of an estrogen-dependent tumor in a mammal comprising administering parenterally to said mammal an amount of a formulation as claimed in claim 6 sufficient to produce the desired effect.

### INTERNATIONAL SEARCH REPORT

International Application N

PCT/FI 92/00339

According to intermentant Parest Charattendron (PC) or to both National Charattendron PC   Int. Cl. 5 A61K3/135; A61K47/48; A61K9/127; A61K9/107			ECT MATTER (If several classification s		
The comment of the published on or the the international filling date or the published on or that the international filling date or the forcement of the published on or that the international filling date or the forcement of the published on or that the international filling date but the forcement or the published on or that the international filling date but the forcement or the published on or that the international filling date but the forcement or the published on or that the international filling date but the forcement or the published on or that the published or the forcement of the published or the forcement of the published or the published or the forcement of the forcement of the published or the forcement of the for					ייחון מען
Milainum Documentation Searched  Int.Cl. 5  A61K  Documentation Symbols  Int.Cl. 5  A61K  Documentation Searched other than Milainum Documentation to the Estate that such Documents are lacided in the Fide's Searched*  III. DOCUMENTS CONSIDERED TO BE RELEVANT*  Category*  Citation of Document, II* with indication, where appenpriate, of the reterent passager II  Redecast to Claim No.D  Chemical ABSTRACTS, vol. 116, no. 16, 20 April 1992, Columbus, Ohio, US; 20 April 1992, Columbus, Ohio, US; abstract no. 158718p, T. LOFTSSON ET Al. * solubilization and stabilization and stabilization of drugs through cyclodextrin complexation* page 442; column 1; 3 ACTA PHARM. NORD. vol. 1991, no. 3,4, pages 215 - 217  ***  **Comment defining has queneral state of the set which is not conditioned to be of particular relevance or conditioned to be of particular relevance or states or other pedial reason (extraction or other pedial reason (extraction or other pedial reason (extraction) and the principle can send decidence, use, exhibition or "F" document of particular relevance, the claimed invention along the tenth of the period of the send decidence of the send decid	Int.Cl	. 5 A61K31/1	35; A61K47/48;	A61K9/1Z/; A6	) TV3\ TU\
Classification System  Int.Cl. 5  A61K  Documentation Scarched other than Milliatum Documentation to the Estant that such Documents are included in the Fields Searched*  III. DOCUMENTS CONSIDERED TO BE RELEVANT*  Category* Classics of Document, "I with Indication, where appropriate, of the referent passager "I Referent to Chin Na.D  P, X  CHEMICAL ABSTRACTS, vol. 116, no. 16, 20 April 1992, Columbus, Ohio, US; abstract no. 158718p, T. LOFTSSON ET AL. 'solubilization and stabilization of drugs through cyclodextrin complexation* page 442 : column 1; & ACTA PHARM. NORD. vol. 1991, no. 3,4, pages 215 - 217  ""A document defining the spentral ratio of the set which is not continued to be of speciment references which is clast to emislish the publication after of another defining to the reference to the product restore the repetiments of the reference which is clast to emislish the publication after of another defining to the reference to the repetiments of the reference to the reference to the repetiments of the reference to the ref	II. FIELDS	SEARCHED			
Int.Cl. 5  A61K  Decommentation Searched other than Milliarum Decommentation to the Extent that such Documents are laddred in the Fields Searched*  III. DOCUMENTS CONSIDERED TO BE RELEVANT?  Category* Cited of Decament, 13 with Indication, where appropriated, of the relevant parasages 12  Relevant to Claim No.D  P, X  CHEMICAL ABSTRACTS, vol. 116, no. 16, 20 April 1992, Columbus, Ohio, US; abstract no. 1597189, T. LOFTSSON ET AL. Solubilitzation and stabilization of drugs through cyclodextrin complexation! page 442; column 1; & ACTA PHARM. NORD. vol. 1991, no. 3,4, pages 215 - 217  -/  **Secular defining the general ratio of the sit which is not considered to be of particular relevance. The entitle document which may three documents of associate relation of order people reaconds of a specific system.  **To document which may three documents of associate relation to order people reaconds to specifically or which is cites to establish the publishing acts of the state of the production state of associate to recomment to the production of associate relation to order people reaconds to specifically or which is cites to establish the publishing acts of the state of the production state of associate to recomment to the production of the state that the publishing of the state o					
Documentation Searched other than Milliamus Documentation to the Estate that such Documents are landsteed in the Fields Searched*  III. DOCUMENTS CONSIDERED TO BE RELEVANT*  Category* Citation of Document, 11 with Indication, where appropriate, of the relevant parages 12 Relevant to Chain No.D  P, X CHEMICAL ABSTRACTS, vol. 116, no. 16, 20 April 1992, Columbus, Ohito, US; 10-12  abstract no. 158718p, T. LOFTSSON ET AL. 'solubilization and stabilization of drugs through cyclodextrin complexation* page 442; column 1; 2 & ACTA PHARM. NORD.  vol. 1991, no. 3,4, pages 215 - 217  **Second to the paragraph of the proceed state of the services of the pages 215 - 217  **Jecunes which may there doubt an printing citating of the conditional to the printing of the paragraph of the paragrap	Classificat	ion System		Classification Symbols	
III. DOCUMENTS CONSIDERED TO BE RELEVANT?  Category* Circles of Document, II with Indication, where appropriate, of the relevant parages II Relevant to Chinn Na.D  P, X CHEMICAL ABSTRACTS, vol. 116, no. 16, 20 April 1992, Columbus, Ohio, US; 10-12  abstract no. 158718p, T. LOFTSSON ET AL. 'solubilization and stabilization of drugs through cyclodextrin complexation' page 442; column 1; & ACTA PHARM. NORD. vol. 1991, no. 3,4, pages 215 - 217  **Special entegories of dited documents: 10	Int.Cl	. 5	A61K		·
Chemical and Document, II with indication, where appropriate, of the relevant parameter II Relevant to Claim No. II P., X  CHEMICAL ABSTRACTS, vol. 116, no. 16, 20 April 1992, Columbus, Ohio, US; 10-12  abstract no. 158718p, T. LOFTSSON ET AL. 'Solubilization and stabilization of drugs through cyclodextrin complexation' page 442; column 1; X  & ACTA PHARM. NORD. vol. 1991, no. 3,4, pages 215 - 217  **Precial categories of dited documents 10 ** ACTA PHARM. NORD. vol. 1991, no. 3,4, pages 215 - 217  **A document defining the general state of the st which is not considered to be of particular relevance statistical filing the general state of the international filing data of the constant of the precial process of the precision of the statistic but published on or size the international filing data of moderate the published on or size the international filing data of the page of the precision of the statistic but published on or size the international filing data of moderate the published state of the statistic but precision or size of the international filing data of moderate the published state of the statistic but precision or size of the international filing data of moderate the published state of the statistic but precision or size of the statistic but precision or size of the international filing data of moderate the published state of the statistic but precision or size of the statistic but precision or the state of precision or the state of the state of statistic but precision or the state of the state of the state of precision of the state of the	<del></del>	· · · · · · · · · · · · · · · · · · ·	Documentation Searched other to the Extent that such Documents	than Minimum Documentation are Included in the Fields Searched <sup>®</sup>	
P,X  CHEMICAL ABSTRACTS, vol. 116, no. 16, 20 April 1992, Columbus, Ohio, US; abstract no. 158718p, T. LOFTSSON ET AL. 'solubilization and stabilization of drugs through cyclodexrin complexation' page 442; column 1; X  & ACTA PHARM. NORD. vol. 1991, no. 3,4, pages 215 - 217  -/  *Special extegories of died document 1 <sup>10</sup> *A document defining the general state of the st which is not conference be at parameters and the parameter of the stream.  *Fe exitie document which may throw doubts on printity claim(s) or which is cited to address the be of parameter between the conference or the printing data or other special reason (as specified)  **Comment of accounter referring to an oral disclasure, use, exhibition or other other needs reason (as specified)  **Of document published prior to the international filling data but lister than the printing data chained or the proposition of the printing data chained in the printing data chaine	III. DOCUI	MENTS CONSIDERE	D TO BE RELEVANT		·
P, X CHEMICAL ABSTRACTS, vol. 116, no. 16, 20 April 1992, Columbus, Ohio, US; abstract no. 158718p, T. LOFTSSON ET AL. 'solubilization and stabilization of drugs through cyclodextrin complexation' page 442; column 1; & ACTA PHARM. NORD. vol. 1991, no. 3,4, pages 215 - 217   **Special extegories of cited documents:  **A** document defaults the predictive devance  **A** document defaults the predictive devance  **Fearth's document which may throw doubte on printity claim(s) or which is cited to establish the publication date another cited to madestant the principle or theory undesting the  **To comment which may throw doubte on printity claim(s) or which is cited to establish the publication date another cited to madestant the principle or theory undesting the  **To comment which may throw doubte on printity claim(s) or which is cited to establish the publication date cancel another cited to madestant the principle or theory undesting to another cited to madestant the principle or theory undesting to another cited to madestant the principle or theory undesting to the calmed lovention cannot be considered to movie as the claimed lovention cannot be considered to involve an inventive step when the document in combined with one or parse other stable  **To comment of particular relevance; the calmed invention cannot be considered to involve an inventive step when the document in combined with one or parse other stable  **To comment of particular relevance; the calmed invention cannot be considered to involve an inventive step when the document in combined with one or parse other stable  **To comment of particular relevance to be received to provide an invention of particular relevance to be received to involve an invention cannot be considered to involve an invention of particular relevance to be received to involve an invention of particular relevance to be received to involve an invention of particular relevance to be considered to involve an invention of particular relevance to be received to involve an invention	Category *	Citation of De	ocument, 11 with indication, where appropri	ate, of the relevant passages 12	Relevant to Claim No.13
abstract no. 158718p, T. LOFTSSON ET AL. 'solubilization and stabilization of drugs through cyclodextrin complexation' page 442; column 1;  & ACTA PHARM. NORD. vol. 1991, no. 3,4, pages 215 - 217   *Special extegories of dited socuments 1 <sup>10</sup> *Are document designed by general state of the art which is not considered to be appearable released.  *For earlier document but published on or after the international filling date or which is tate to establish the publication also of another which is tate to establish the publication also of another charms or state the international filling date or which is tate to establish the publication also of another charms or a state of the art which is not considered to many throw doubts on priority case and not in conflict with the application but disable to the considered to many the comment of another which is comment to enabled with one or other under the comment of the same particular relevance, the chaims discrement, such combinations being obvious to a person skilled in the set.  **To document spublished prior to the international filling date but later than the priority date chaimed  **To document spublished prior to the international filling date but later than the priority date chaimed  **To document spublished prior to the international filling date but later than the priority date chaimed  **To document spublished prior to the international filling date but later than the priority date chaimed  **To document sembler of the same particular relevance; the chaimed invention cannot be considered to involve an inventive step when the document is combined with one or other such focuments, such combinations being obvious to a person skilled in the set.  **To document published on the international Search Report  **To document published on the international Search Report  **To document publishe		CHEMICA	L ABSTRACTS, vol. 116,	no. 16,	
"Special extegories of cited documents; 10  "A" document defining the general state of the art which is not considered to be of particular relevance  E earlier document bot published on or siter the international filing date or pintrily date and not in conflict with the application but cited to measurant the pintrily date of mother selected to make that the pintrily claim(s) or which is cited to establish the publication date of another chisting or other special reason (as specified)  "O" document published prior to the international filing date but later than the priority date chalmed filing date but later than the priority date chalmed Search  IV. CERTIFICATION  Date of the Actual Completion of the International Search  12 MARCH 1993  International Searching Amshority  T ister focument published after the international filing date or priority date and not in conflict with the application but cited to measurant the principle or theory underlying the invention of counter to exclude a portion factor or cannot be considered novel or cannot be considered to involve an inventive step when the document to exclude a priority date chalmed invention cannot be considered to involve an inventive step when the document to exclude a priority date chalmed invention cannot be considered to involve an inventive step when the document to exclude a priority date chalmed invention cannot be considered to involve an inventive step when the document to exclude a priority date chalmed invention cannot be considered to involve an inventive step when the document to exclude a priority and the full priority date chalmed invention cannot be considered to involve an inventive step when the document to exclude a priority date chalmed invention cannot be considered to involve an inventive step when the document to exclude a priority date chalmed invention cannot be considered to involve an inventive step when the document to exclude a priority date chalmed invention cannot be considered to involve an inventive step and the full priority d	X	T. LOFT: stabili; cyclode: page 44 & ACTA   vol. 19	SSON ET AL. 'solubiliza zation of drugs through xtrin complexation' 2 ;column 1 ; PHARM. NORD. 91, no. 3,4,	ation and	
"A" document defining the general state of the art which is not considered to be of particular relevance  "E" earlier document but published on or after the international filling date  "I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another changes or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means  "F" document published prior to the international filling date but later than the priority date chained  IV. CERIFICATION  Date of the Actual Completion of the International Search  12 MARCH 1993  Date of Mailing of this International Search Signature of Asthorized Officer  Signature of Asthorized Officer				<b>-/</b>	
"A" document defining the general state of the art which is not considered to be of particular relevance  "E" earlier document but published on or after the international filling date  "I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another changes or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means  "F" document published prior to the international filling date but later than the priority date chained  IV. CERIFICATION  Date of the Actual Completion of the International Search  12 MARCH 1993  Date of Mailing of this International Search Signature of Asthorized Officer  Signature of Asthorized Officer					
Date of the Actual Completion of the International Search  12 MARCH 1993  3 7, 03, 32  International Searching Authority  Signature of Authoritical Officer	"A" doc "E" ear fill "I" doc cha "O" doc pt the "P" doc late	nument defining the ger addered to be of partice tiler document but publi- ing date unsent which may thro the is cited to establish tion or other special re- cursent referring to an er teams: unsent published prior is or than the priority date	neral state of the art which is not alar relevance sheed on or after the international or doubts on priority claim(s) or the publication date of another ason (as specified) oral disclosure, may exhibition or to the international filing date but	or priority data and not in conflict with a cited to understand the principle or their minimum of particular relevance; the cla cannot be considered novel or cannot be involve an inventive step  "Y" document of particular relevance; the cla cannot be considered to involve an inventive step document is combined to involve an inventive and the state of the considered to involve an inventive and the state of	he application but ry underlying the insel invention considered to limed invention tive step when the other such docu- o a person skilled
12 MARCH 1993 3 P. D. 32 International Searching Authority Signature of Authorized Officer	IV. CERTI	FICATION			
DENT V. F	Date of the	·		1 "	rch Report
DENT V. F	International	I Searching Authority	<del></del>	Signature of Anthorized Officer	
			IN PATENT OFFICE	1 -	

Form PCT/ISA/210 (second short) (Japaney 1985

m nocime	INTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)	
Catagory*	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
carigory		
x	JOURNAL OF CHROMATOGRAPHY, BIOMEDICAL APPLICATIONS vol. 414, no. 1, 20 February 1987,	1-2, 10-12
	AMSTERDAM (NL) pages 192 - 196 p n ARMSTRONG ET AL, 'separation of	
	tamoxifen geometric isomers and metabolites by bonded-phase beta-cyclodextrin chromatography	
	see the whole document	
Å ·	WO,A,9 117 749 (BAYLOR COLLEGE OF MEDICINE)	1-6, 10-12
	28 November 1991 see page 1, line 5 - line 10 see page 39, line 25 - page 41, line 3	
x	FEBS LETTERS	1,2
•	vol. 274, no. 1,2, November 1990, AMSTERDAM (NL)	
	pages 107 - 110 H. WISEMAN ET AL. 'mechanism of inhibition of lipid peroxidation by tamoxifen and	
Y .	4-hydroxytamoxifen introduced into Tiposomes' see the whole document	7-9
	DE, A, 3 331 459 (FINK ET AL.)	1,2
Y	1 March 1984 see claim. 1	
Y	EP,A,O 355 604 (LEDERLE (JAPAN) ET AL.) 28 February 1990	1,2
Y .	see claims 1-20 FR,A,2 502 951 (SANDOZ SA)	1,2
•	8 October 1982 see page 24; claim 2 see page 28, line 2 - line 3	
Y	WO,A,9 006 106 (PATRINOVE) 14 June 1990 see page 3, line 24 - line 36	7-9
	ace page of time at	
.		

International	application	No.

#### INTERNATIONAL SEARCH REPORT

PCT/FI 92/00339

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This int	ernational search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: ALTHOUGH CLAIMS 10-12 ARE DIRECTED TO A METHOD OF TREATMENT OF THE HUMAN/
_	ANIMAL BODY THE SEARCH HAS BEEN CARRIED OUT AND BASED ON THE ALLEGED EFFECT S OF THE COMPOSITION.
2	Claims Not.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
,	
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Int	ernational Searching Authority found multiple inventions in this international application, as follows:
ı. 🗀	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. 🗌	As all searchable claims could be searches without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
_	
Remark o	on Protest The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)

# ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

FI 9200339 SA 68161

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.

The members are as contained in the European Patent Office EDP file on
The European-Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

12/03/93

Patent document cited in search report	Publication date	Patent family member(s)		Publication date	
WO-A-9117749	28-11-91	AU-A-	7963691 0528975	10-12-91 03-03-93	
DE-A-3331459	01-03-84	None			
EP-A-0355604	28-02-90	JP-A- US-A- US-A-	2138211 5004756 5182267	28-05-90 02-04-91 26-01-93	
FR-A-2502951	08-10-82	CH-A- CH-A- AU-A- AU-A- BE-A- CA-A- DE-A- FR-A- GB-A, B GB-A, B JP-A- NL-A- SE-A-	653256 647149 6508486 564570 8233482 892709 1192496 3212053 2572933 2098865 2148711 57181007 8201413 8202172	31-12-85 15-01-85 12-03-87 20-08-87 14-10-82 30-09-82 27-08-85 21-10-82 16-05-86 01-12-82 05-06-85 08-11-82 07-10-82	
WO-A-9006105	14-06-90	FR-A-	2640137	15-06-90	
e.		. •			
				•	

C Fer more details about this annux : see Official Journal of the European Patent Office, No. 12/22

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

# **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
OTHER:

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.